[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,342
  • Shares Outstanding, K 3,983
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,910 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta -0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.88
  • Number of Estimates 2
  • High Estimate $-0.82
  • Low Estimate $-0.94
  • Prior Year $-7.08
  • Growth Rate Est. (year over year) +87.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9293 +18.37%
on 07/29/26
1.2173 -9.64%
on 08/10/26
+0.0400 (+3.77%)
since 07/24/26
3-Month
0.9293 +18.37%
on 07/29/26
1.2250 -10.20%
on 07/16/26
+0.0300 (+2.80%)
since 05/22/26
52-Week
0.8750 +25.71%
on 05/11/26
11.6000 -90.52%
on 09/10/25
-10.6200 (-90.61%)
since 08/22/25

Most Recent Stories

More News
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.68 (+2.34%)
SER : 2.63 (-8.36%)
GANX : 2.00 (-0.25%)
BIOA : 9.38 (-1.05%)
OSTX : 1.5500 (-2.52%)
VTVT : 33.89 (+1.91%)
MASS : 10.92 (+2.25%)
PYPD : 4.99 (-2.25%)
TKNO : 7.34 (-0.27%)
OVID : 2.82 (+0.71%)
MDCX : 0.2574 (-5.30%)
EQ : 2.20 (-4.76%)
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

– Study on track to begin later this year –

REVB : 1.1000 (+0.92%)
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to...

REVB : 1.1000 (+0.92%)
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to...

REVB : 1.1000 (+0.92%)
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)
Revelation Biosciences Announces Adoption of Stockholder Rights Plan

SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)
Revelation Biosciences Expands Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat...

REVB : 1.1000 (+0.92%)

Business Summary

Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra...

See More

Key Turning Points

3rd Resistance Point 1.1861
2nd Resistance Point 1.1531
1st Resistance Point 1.1265
Last Price 1.1000
1st Support Level 1.0669
2nd Support Level 1.0339
3rd Support Level 1.0073

See More

52-Week High 11.6000
Fibonacci 61.8% 7.5030
Fibonacci 50% 6.2375
Fibonacci 38.2% 4.9720
Last Price 1.1000
52-Week Low 0.8750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.